查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011567

癌症免疫疗法市场：按治疗方法、作用机制、治疗阶段、给药途径、适应症和最终用户划分－全球市场预测（2026-2032 年）

Cancer Immunotherapy Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Route Of Administration, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，癌症免疫疗法市场价值将达到 817.4 亿美元，到 2026 年将成长至 861.4 亿美元，到 2032 年将达到 1,207.5 亿美元，复合年增长率为 5.73%。

主要市场统计数据
基准年 2025 817.4亿美元
预计年份：2026年 861.4亿美元
预测年份 2032 1207.5亿美元
复合年增长率 (%) 5.73%

本文对癌症免疫疗法的发展历程进行了基本概述，重点在于临床进展、营运挑战以及相关人员。

在持续的临床进展和监管里程碑的推动下，癌症免疫疗法已从一个充满前景的科学概念发展成为肿瘤治疗的核心支柱。过去十年，基于免疫的治疗方法重新定义了骨髓恶性肿瘤和日益增多的固态肿瘤的治疗模式，并在许多患者亚群中取得了显着且持久的疗效。细胞工程、精准生物标记检测以及不断扩充的单株抗体、疫苗和病毒载体库的进步，推动了这项发展。

重塑免疫肿瘤学的关键趋势包括技术创新、个人化策略以及整个价值链运作的现代化。

癌症免疫疗法的格局正在经历一场变革性的转变，这主要得益于科学突破、监管调整以及相关人员期望的不断变化。首先，细胞疗法，特别是嵌合体抗原受体T细胞（CAR-T细胞）疗法的成熟，使其应用范围从最初在血液系统疾病领域的成功扩展到包括基因修饰构建体和异基因移植等方法，旨在扩大其适用范围并缩短治疗时间。同时，查核点抑制剂的进展也得到了更复杂的免疫调节方法的补充，例如双特异性分子和新一代抗体，旨在提高特异性并降低毒性。

评估 2025 年关税政策的变化将如何影响免疫疗法所有相关人员的供应链、製造策略和市场定位。

美国2025年实施的新关税政策可能会透过改变成本、供应链结构和采购决策，对整个癌症免疫疗法生态系统产生累积影响。生物製药和细胞疗法生产所需的关键材料——包括专用试剂、一次性耗材、生物製程设备和低温运输物流服务——通常来自世界各地。进口关税的增加和海关摩擦的加剧可能会推高整体成本，迫使企业调整库存，并加速选择替代供应商。因此，采购前置作业时间可能会延长，从而对研发进度带来压力，因为紧急时应对计画将成为专案风险管理的关键要素。

全面的細項分析揭示了治疗方法、作用机制、适应症和临床实践如何推动研发和商业化路径。

一套精细的细分框架揭示了临床差异和商业性机会如何在不同的治疗方法类型、作用机制、治疗线、给药途径、适应症和最终用户之间相互交织。基于治疗方法类型，该计画涵盖癌症疫苗、CAR-T疗法、CTLA-4抑制剂、溶瘤病毒疗法、PD-1抑制剂和PD-L1抑制剂，每种疗法都面临独特的研发挑战和临床定位考量。疫苗策略着重于抗原选择和递送平台，而细胞疗法则需要生产创新和以患者为中心的物流。基于作用机制，该领域涵盖过继性细胞疗法、免疫查核点抑制剂、细胞激素疗法、溶瘤病毒疗法和疫苗疗法。这种机制的多样性要求制定个体化的生物标记策略、安全监测框架和联合治疗方案，以在控制毒性的同时最大限度地提高疗效。

全球免疫疗法市场的区域性趋势，以及有关监管合作、证据产生和生产的策略考量。

区域趋势影响临床试验设计、监管互动、生产投资和市场准入策略，因此需要采取因地制宜的方法，以应对法律规范、报销机制和医疗基础设施等问题。在美洲，监管机构和保险公司优先考虑可靠的疗效证据和真实世界数据，而大规模研究网络和创投则加速了首次人体试验和商业化的进程。因此，各机构通常优先在北美进行早期临床检验和与保险公司的合作，以支持更广泛的市场进入计画。此外，美洲地区集中的生产和物流能力有利于快速扩大规模，但也需要与医院和专科诊所的管理模式进行密切协调。

竞争动态与伙伴关係策略：揭示执行、製造规模与平台差异化如何驱动长期价值创造

竞争格局的特点是：既有成熟的免疫肿瘤学领导企业，也有许多致力于平台创新、特定适应症或联合治疗的新兴生物技术公司。成熟的研发公司利用其庞大的临床数据集和製造地，确保适应症的广泛拓展，并与支付方协商基于价值的合约。而小规模的公司则倾向于专注于差异化生物学、新型抗原标靶或能够提高生产效率和患者可及性的基础技术。

为协调临床开发、生产韧性和支付方合作，以加速部署和价值实现，提出切实可行的策略建议。

规划免疫肿瘤学下一阶段的领导者应采取整合科学、营运和商业化的整合策略。首先，应优先考虑模组化开发计划，以便采用适应性试验设计和基于生物标记的队列研究，从而在保持柔软性的同时，展现显着的疗效，并拓展适应症和联合治疗。儘早与监管机构和支付方沟通至关重要，以便确定具有临床意义的终点和可接受的证据包，从而支持可持续的报销结果。其次，应透过考虑区域生产基地、自动化和供应商多元化来增强生产的韧性，从而降低地缘政治因素和关税带来的干扰，同时确保品质和合规标准。

透过整合专家访谈、监管分析和营运评估等多源调查方法，得出可操作的产业见解。

本研究采用综合分析方法，结合科学文献、监管指南、专家访谈和营运调查方法，建构与产业实践相符的连贯叙事。关键的定性资料包括对临床研究人员、生产经理、保险公司和商业负责人的结构化访谈，揭示了研发和交付过程中实际存在的障碍和驱动因素。除访谈外，对同行评审文章、监管核准和公开文件的系统性回顾，确保分析能够反映最新的科学进展和政策变化。

结论强调，整合科学、实务和商业性策略对于充分发挥免疫肿瘤学的真正潜力至关重要。

癌症免疫疗法正处于一个转折点，科学进步必须与卓越的营运和清晰的策略相辅相成，才能保持其发展势头。儘管新的治疗方法和联合治疗策略不断拓展治疗选择，但其最终影响取决于相关人员能否成功应对复杂的生产要求、多样化的监管预期以及不断变化的支付方证据需求。那些积极调整研发策略，将基于生物标记的患者筛选、稳健的供应链以及符合支付方要求的证据纳入其中的机构，将更有能力将临床潜力转化为可持续的患者获益。

目录

第一章 引言

第二章 分析方法

  • 分析设计
  • 分析框架
  • 市场规模预测
  • 数据三角测量
  • 分析结果
  • 分析的前提条件
  • 分析的局限性

第三章执行摘要

  • 首席体验长的观点
  • 市场规模和成长趋势
  • 市占率分析（2025 年）
  • FPNV定位矩阵（2025）
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入（GTM）策略

第五章 市场洞察

  • 消费者分析与最终用户观点
  • 消费者体验基准测试
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第六章：美国关税的累积影响（2025 年）

第七章：人工智慧（AI）的累积影响（2025 年）

第八章：癌症免疫疗法市场：依治疗方法划分

  • 癌症疫苗
  • CAR-T疗法
  • CTLA-4抑制剂
  • 溶瘤病毒疗法
  • PD-1抑制剂
  • PD-L1抑制剂

第九章：按作用机制分類的癌症免疫疗法市场

  • 过继性细胞疗法
  • 查核点抑制剂
  • 细胞激素疗法
  • 溶瘤病毒疗法
  • 疫苗疗法

第十章：依治疗阶段分類的癌症免疫疗法市场

  • 一线
  • 从力线开始
  • 第二行
  • 三线

第十一章：癌症免疫疗法市场：依给药途径划分

  • 肿瘤内部
  • 静脉
  • 皮下

第十二章：癌症免疫疗法市场：依适应症划分

  • 骨髓恶性肿瘤
    • 白血病
    • 淋巴瘤
    • 多发性骨髓瘤
  • 固体癌
    • 乳癌
    • 结肠癌
    • 肺癌
    • 恶性黑色素瘤

第十三章：癌症免疫疗法市场：依最终用户划分

  • 医院
  • 研究机构
  • 专科诊所

第十四章 癌症免疫疗法市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 癌症免疫疗法市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 癌症免疫疗法市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国癌症免疫疗法市场

第十八章：中国癌症免疫疗法市场

第十九章 竞争情势

  • 市场集中度分析（2025 年）
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析（2025 年）
  • 产品系列分析（2025 年）
  • 基准分析（2025 年）
  • Amgen Inc.
  • AstraZeneca PLC
  • BeiGene, Ltd.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Cellectis SA
  • Daiichi Sankyo Company, Limited
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson
  • Kite Pharma
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Seagen Inc.
Product Code: MRR-4330CC794A6B

The Cancer Immunotherapy Market was valued at USD 81.74 billion in 2025 and is projected to grow to USD 86.14 billion in 2026, with a CAGR of 5.73%, reaching USD 120.75 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 81.74 billion
Estimated Year [2026] USD 86.14 billion
Forecast Year [2032] USD 120.75 billion
CAGR (%) 5.73%

Foundational overview of cancer immunotherapy evolution highlighting clinical progress, operational challenges, and strategic imperatives for stakeholders

Cancer immunotherapy has moved from a promising scientific concept to a central pillar of oncology care, driven by a sustained wave of clinical advances and regulatory milestones. Over the past decade, therapies that harness the immune system have redefined treatment paradigms for both hematologic malignancies and a growing set of solid tumors, creating meaningful durable responses for many patient subgroups. This evolution has been propelled by a convergence of technological improvements in cell engineering, precision biomarker assays, and an expanding repertoire of monoclonal antibodies, vaccines, and viral vectors.

As research continues to mature, stakeholders across industry, academia, and clinical practice face a new set of operational and strategic questions. Developers must balance the scientific complexity of combination regimens with the logistical demands of manufacturing personalized products, while payers and health systems increasingly seek evidence of long-term value and manageable treatment pathways. Consequently, organizations planning therapeutics or services in this space must integrate translational science with pragmatic considerations such as supply chain resilience, regulatory alignment, and patient access models to realize clinical benefit at scale.

This executive summary synthesizes current dynamics, regulatory and commercial headwinds, and actionable avenues for stakeholders to navigate the changing competitive and clinical environment. The goal is to offer a clear, evidence-aligned narrative that supports decision-making without obscuring the heterogeneity of tumor biology, therapeutic modalities, or care delivery contexts.

Critical transformative trends reshaping immuno-oncology including technological innovation, personalized strategies, and operational modernization across the value chain

The landscape of cancer immunotherapy is undergoing transformative shifts driven by a combination of scientific breakthroughs, regulatory adaptations, and evolving stakeholder expectations. First, the maturation of cell therapies, particularly chimeric antigen receptor T cells, has expanded beyond early successes in hematologic indications toward engineered constructs and allogeneic approaches designed to broaden applicability and reduce time-to-treatment. Parallel advances in checkpoint inhibition have been complemented by more nuanced approaches to immune modulation, including bispecific molecules and next-generation antibody formats that seek improved specificity and toxicity profiles.

Second, translational science is accelerating personalized approaches-neoantigen vaccines, tumor-infiltrating lymphocyte optimization, and multiplexed biomarker-driven trials-that demand more intricate trial designs and real-world evidence capture. As a result, collaborations that pair clinical expertise with diagnostic and bioinformatics capabilities are becoming essential. Third, manufacturing and supply chain innovations, including automation, closed-system processing, and regionalized production hubs, are shifting how developers plan scale-up and commercialization, reducing some barriers but introducing new capital and regulatory complexities.

Fourth, market and payer dynamics are influencing how therapies are evaluated, with a pronounced emphasis on long-term outcomes, value-based contracting, and healthcare system integration. Collectively, these shifts are redefining competitive advantage: scientific novelty alone is insufficient without credible development pathways, robust operational execution, and payer-aligned evidence generation. The combination of these elements will determine which programs progress from clinical promise to sustainable clinical and commercial impact.

Assessment of how evolving tariff policies in 2025 could alter supply chains, manufacturing strategies, and commercial positioning across immunotherapy stakeholders

The introduction of new tariff policies in the United States during 2025 has the potential to exert a cumulative impact across the cancer immunotherapy ecosystem by altering costs, supply chain configurations, and sourcing decisions. Key inputs for biologic and cell therapy manufacturing-specialized reagents, single-use consumables, bioprocessing equipment, and cold-chain logistics services-are often sourced globally. An increase in import duties or customs friction can elevate landed costs, prompt inventory rebalancing, and accelerate efforts to qualify alternative suppliers. Consequently, research and development timelines may experience pressure as procurement lead times extend and contingency planning becomes a material component of program risk management.

In response to tariff-driven cost pressures, many stakeholders may pursue nearshoring or domestic manufacturing partnerships to reduce exposure to cross-border trade volatility and maintain control over critical production steps. Such strategic reorientation could increase upfront capital deployment but may also yield long-term advantages in supply continuity and regulatory oversight. Moreover, higher input costs will heighten scrutiny of manufacturing efficiency, process intensification, and yield optimization, incentivizing investments in automation, closed systems, and digital monitoring to protect margins while preserving quality.

Finally, the cumulative effects of tariff changes will likely influence commercial strategies including pricing negotiations, payer contracting, and the staging of product launches. Organizations that proactively reassess supplier relationships, prioritize resilient manufacturing pathways, and transparently demonstrate cost and outcome value to payers will be better positioned to mitigate financial and operational disruption in a tariff-influenced market environment.

Comprehensive segmentation analysis revealing where therapeutic modalities, mechanisms, indications, and care settings create distinct development and commercialization pathways

A nuanced segmentation framework illuminates where clinical differentiation and commercial opportunity intersect across therapy types, mechanisms, lines of therapy, administration routes, indications, and end users. Based on Therapy Type, programs span Cancer Vaccines, CAR-T Therapy, CTLA-4 Inhibitors, Oncolytic Virus Therapy, PD-1 Inhibitors, and PD-L1 Inhibitors, each presenting distinct development challenges and clinical positioning considerations; vaccine strategies emphasize antigen selection and delivery platforms, whereas cell therapies demand manufacturing innovation and patient-centric logistics. Based on Mechanism Of Action, the field encompasses Adoptive Cell Transfer, Checkpoint Inhibitors, Cytokine Therapy, Oncolytic Virus Therapy, and Vaccine Therapy, and this mechanistic diversity requires tailored biomarker strategies, safety monitoring frameworks, and combination hypotheses to maximize efficacy while managing toxicity.

Based on Line Of Therapy, therapeutic opportunities and payer expectations vary significantly between First Line, Second Line, Third Line, and Fourth Line And Beyond, with earlier-line approvals necessitating higher-evidence thresholds and clearer comparative benefit; consequently, developers should plan sequencing strategies that align trial design with expected reimbursement scenarios. Based on Route Of Administration, distinctions among Intratumoral, Intravenous, and Subcutaneous approaches influence clinical workflow, patient burden, and site-of-care economics, shaping adoption pathways across hospitals and clinics. Based on Indication, the landscape bifurcates into Hematologic Malignancies and Solid Tumors, with the former further segmented into Leukemia, Lymphoma, and Multiple Myeloma and the latter into Breast Cancer, Colorectal Cancer, Lung Cancer, and Melanoma, each indication presenting unique tumor microenvironmental considerations and biomarker profiles that inform patient selection and combination strategies.

Based on End User, hospitals, research institutes, and specialty clinics play differentiated roles in clinical trial accrual, product administration, and post-market evidence generation; hospitals often lead high-complexity administrations and inpatient monitoring, research institutes drive translational science and early-phase innovation, while specialty clinics enable outpatient delivery models that can improve throughput and patient convenience. Together, this segmentation highlights where scientific focus, operational investment, and commercial engagement should be concentrated to address unmet needs and optimize development trajectories.

Region-specific dynamics and strategic considerations for regulatory engagement, evidence generation, and manufacturing across global immunotherapy markets

Regional dynamics shape clinical trial design, regulatory engagement, manufacturing investment, and access strategies, demanding region-specific approaches that accommodate regulatory frameworks, reimbursement systems, and healthcare infrastructure. In the Americas, regulatory agencies and payers emphasize robust outcomes evidence and real-world data, while large research networks and venture and corporate investment have accelerated first-in-human studies and commercialization pathways; consequently, organizations often prioritize North American clinical validation and payer dialogue early in development to underpin broader market access plans. The Americas also host concentrated manufacturing and logistics capabilities, which supports rapid scale-up but requires careful coordination with hospital and specialty clinic administration models.

In Europe, Middle East & Africa, regulatory diversity and heterogeneous reimbursement environments necessitate multi-jurisdictional regulatory strategies and differentiated pricing approaches. European health technology assessment bodies place particular weight on comparative effectiveness and cost-effectiveness assessments, influencing trial endpoints and evidence generation plans. Additionally, emerging markets across the Middle East & Africa present opportunities for capacity building and pilot access programs but require tailored operational partnerships and investment in cold-chain and training infrastructure.

In Asia-Pacific, accelerated trial recruitment, growing biotech innovation hubs, and increasing local manufacturing capacity are shaping regional strategies; countries in the region vary in regulatory timelines and local clinical expectations, prompting companies to calibrate development plans to leverage speed to data while ensuring quality and regulatory alignment. Cross-region collaboration, such as bridging studies and harmonized regulatory submissions, can reduce time-to-patient access and support global labeling strategies, provided sponsors anticipate regional clinical practice patterns and payer requirements.

Competitive dynamics and partnership-based strategies revealing how execution, manufacturing scale, and platform differentiation drive long-term value creation

The competitive landscape is characterized by incumbent immuno-oncology leaders and a large cohort of emerging biotechs pursuing platform innovation, niche indications, or combination regimens. Established developers have leveraged deep clinical datasets and manufacturing footprints to secure broad label expansions and to negotiate value-based arrangements with payers, whereas smaller firms often focus on differentiated biology, novel antigen targets, or enabling technologies that improve manufacturability and patient access.

Across the ecosystem, strategic partnerships between developers, contract development and manufacturing organizations, diagnostic providers, and academic centers have become increasingly common as a means to accelerate clinical translation and de-risk capital-intensive steps. These alliances frequently address discrete gaps such as vector manufacturing, T-cell engineering, or companion diagnostic validation, enabling faster trial starts and improved operational scalability. In parallel, service providers offering automation, analytics, and patient management tools are emerging as critical enablers for both personalized and standardized therapeutic approaches.

Intellectual property positioning, clinical differentiation, and demonstrated ability to execute complex supply chains remain decisive factors in value creation. Firms that combine robust clinical programs with scalable manufacturing, payer-aligned evidence strategies, and strong collaborative networks will retain strategic advantage. At the same time, new entrants that deliver platform-level improvements in safety, cost, or ease-of-use can rapidly gain relevance through licensing or co-development agreements.

Actionable strategic recommendations for aligning clinical development, manufacturing resilience, and payer engagement to accelerate adoption and value realization

Leaders planning to navigate the next phase of immuno-oncology advancement should adopt integrated strategies that align science, operations, and commercialization. First, prioritize modular development plans that allow for adaptive trial designs and biomarker-enriched cohorts to demonstrate meaningful benefit while preserving flexibility for label expansion and combinations. Early engagement with regulatory bodies and payers is essential to define clinically relevant endpoints and acceptable evidence packages that support durable reimbursement outcomes. Second, invest in manufacturing resilience by exploring regional production hubs, automation, and supplier diversification to mitigate geopolitical and tariff-related disruption while maintaining quality and compliance standards.

Third, cultivate strategic partnerships spanning diagnostics, contract manufacturing, and clinical network collaborators to accelerate translational pathways and reduce time-to-patient. By leveraging external expertise, organizations can focus internal resources on core differentiators such as target biology and clinical execution. Fourth, design patient-centric delivery models that reduce burden, enable outpatient administration where feasible, and integrate digital tools for monitoring and outcomes capture. These models enhance adherence and produce real-world evidence that reinforces payer negotiations and clinical adoption.

Finally, maintain disciplined portfolio management that balances novel, high-risk science with programs offering clearer paths to clinical and commercial viability. Establishing cross-functional governance for prioritization, risk monitoring, and go-to-market readiness will enable faster, more confident decisions as the scientific and policy environment evolves.

Robust multi-source research methodology integrating expert interviews, regulatory analysis, and operational assessments to generate actionable industry insights

The research synthesis draws on a multi-source methodology designed to integrate scientific literature, regulatory guidance, expert interviews, and operational insights to build a coherent narrative aligned with industry practice. Primary qualitative inputs included structured interviews with clinical investigators, manufacturing leads, payers, and commercial strategists to surface pragmatic barriers and enablers across development and delivery pathways. These interviews were complemented by a systematic review of peer-reviewed publications, regulatory approvals, and public filings to ensure the analysis reflects recent scientific advances and policy shifts.

Additionally, the methodology incorporated operational assessments of manufacturing and supply chain considerations through engagements with contract development and manufacturing organizations and logistics specialists. This allowed for an informed appraisal of practical constraints such as lead times, cold-chain requirements, and capacity scaling. Analytical synthesis emphasized cross-validation, pairing qualitative perspectives with documented clinical and regulatory milestones to reduce bias and enhance actionability. Throughout the research process, attention was paid to transparency of assumptions, the provenance of insights, and the identification of areas where further primary data collection could refine conclusions.

This multi-dimensional approach enables stakeholders to interpret findings in the context of their own strategic priorities while recognizing the heterogeneity inherent in therapeutic modalities, geographic markets, and care delivery models.

Concluding synthesis emphasizing the necessity of integrated scientific, operational, and commercial strategies to realize the full promise of immuno-oncology

Cancer immunotherapy stands at an inflection point where scientific progress must be matched by operational excellence and strategic clarity to sustain momentum. Novel modalities and combination strategies continue to expand the therapeutic toolkit, but their ultimate impact will depend on the ability of stakeholders to navigate complex manufacturing requirements, diverse regulatory expectations, and evolving payer evidence demands. Organizations that proactively adapt development strategies to incorporate biomarker-driven patient selection, resilient supply chains, and payer-aligned evidence will be better positioned to translate clinical promise into durable patient benefit.

Moreover, the growing interplay between regional regulatory environments and global commercialization strategies underscores the necessity of harmonized evidence plans and flexible manufacturing footprints. As new policy and trade dynamics emerge, including tariff considerations, the capacity to rapidly adjust sourcing and production approaches becomes a competitive advantage. In conclusion, the path forward requires integrated leadership across science, operations, and commercial functions to ensure that innovations in immuno-oncology are delivered efficiently, equitably, and with demonstrable value for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Immunotherapy Market, by Therapy Type

  • 8.1. Cancer Vaccines
  • 8.2. CAR-T Therapy
  • 8.3. CTLA-4 Inhibitors
  • 8.4. Oncolytic Virus Therapy
  • 8.5. PD-1 Inhibitors
  • 8.6. PD-L1 Inhibitors

9. Cancer Immunotherapy Market, by Mechanism Of Action

  • 9.1. Adoptive Cell Transfer
  • 9.2. Checkpoint Inhibitors
  • 9.3. Cytokine Therapy
  • 9.4. Oncolytic Virus Therapy
  • 9.5. Vaccine Therapy

10. Cancer Immunotherapy Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Fourth Line And Beyond
  • 10.3. Second Line
  • 10.4. Third Line

11. Cancer Immunotherapy Market, by Route Of Administration

  • 11.1. Intratumoral
  • 11.2. Intravenous
  • 11.3. Subcutaneous

12. Cancer Immunotherapy Market, by Indication

  • 12.1. Hematologic Malignancies
    • 12.1.1. Leukemia
    • 12.1.2. Lymphoma
    • 12.1.3. Multiple Myeloma
  • 12.2. Solid Tumors
    • 12.2.1. Breast Cancer
    • 12.2.2. Colorectal Cancer
    • 12.2.3. Lung Cancer
    • 12.2.4. Melanoma

13. Cancer Immunotherapy Market, by End User

  • 13.1. Hospitals
  • 13.2. Research Institutes
  • 13.3. Specialty Clinics

14. Cancer Immunotherapy Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cancer Immunotherapy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Immunotherapy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cancer Immunotherapy Market

18. China Cancer Immunotherapy Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amgen Inc.
  • 19.6. AstraZeneca PLC
  • 19.7. BeiGene, Ltd.
  • 19.8. bluebird bio, Inc.
  • 19.9. Bristol-Myers Squibb Company
  • 19.10. Cellectis S.A.
  • 19.11. Daiichi Sankyo Company, Limited
  • 19.12. Fate Therapeutics, Inc.
  • 19.13. Gilead Sciences, Inc.
  • 19.14. GlaxoSmithKline plc
  • 19.15. Iovance Biotherapeutics, Inc.
  • 19.16. Johnson & Johnson
  • 19.17. Kite Pharma
  • 19.18. Merck KGaA
  • 19.19. Novartis AG
  • 19.20. Pfizer Inc.
  • 19.21. Regeneron Pharmaceuticals, Inc.
  • 19.22. Roche Holding AG
  • 19.23. Sanofi
  • 19.24. Seagen Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 190. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 217. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 226. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)